Secondary hemophagocytic lymphohistiocytosis: Do we really need chemotherapeutics for all patients?

Journal of Pediatric Hematology/Oncology

Volumn 39, Issue 2, 2017, Pages e106-e109

  Haytoglu, Zeliha ^a   Yazici, Nalan ^b   Erbay, Ayse ^b  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

hemophagocytic lymphohistiyocytosis; outcome assessment; secondary hemophagocytic lymphohistiocytosis

Indexed keywords

AMPHOTERICIN B; FERRITIN; IMMUNOGLOBULIN; STEROID; BIOLOGICAL MARKER; CYTOTOXIN; IMMUNOSUPPRESSIVE AGENT;

ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; ERYTHROPHAGOCYTOSIS; FEMALE; FERRITIN BLOOD LEVEL; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERFERRITINEMIA; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEUTROPENIA; PLASMAPHERESIS; PROGNOSIS; SCHOOL CHILD; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; BLOOD; HEALTH SERVICE; HOSPITALIZATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MORTALITY; ORGAN DYSFUNCTION SCORE; PRESCHOOL CHILD; PREVENTION AND CONTROL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

BIOMARKERS; CHILD; CHILD, PRESCHOOL; CYTOTOXINS; FEMALE; FERRITINS; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MEDICAL OVERUSE; ORGAN DYSFUNCTION SCORES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85008350887     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000740     Document Type: Article

References (20)

1. Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16:82-89.
2. Henter JI, Horne AC, AricóM, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-131.
3. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115:461-473.
4. Yamamoto K, Ishii E, Horiuchi H, et al. Mutations of syntaxin 11 and SNAP23 genes as causes of familial hemophagocytic lymphohistiocytosis were not found in Japanese people. J Hum Genet. 2005;50:600-603.
5. Kleynberg RL, Schiller GJ. Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol. 2012;10:726-732.
6. Ansuini V, Rigante D, Esposito S. Debate around infectiondependent hemophagocytic syndrome in paediatrics. BMC Infect Dis. 2013;13:15.
7. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139:713-727.
8. Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. 2009;10: 387-392.
9. Demirkol D, Yildizdas D, Bayrakci B, et al. Turkish Secondary HLH/MAS Critical Care Study Group: hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care. 2012;16:R52.
10. Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/ multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med. 2014;15: 401-408.
11. Leteurtre S, Duhamel A, Grandbastien B, et al. Paediatric logistic organ dysfunction (PELOD) score. Lancet. 2003;362: 192-197.
12. Bennett TD, Hayward KN, Farris RW, et al. Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients. Pediatr Crit Care. 2011;12: 233-236.
13. Otrock ZY, Eby CS. Clinical characteristics, prognostic factors and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90:220-224.
14. Halstead ES, Carcillo JA, Schilling B, et al. Reduced frequency of CD56 dim CD16 postnatural killer cells in pediatric systemic inflammatory response syndrome/sepsis patients. Pediatr Res. 2013;74:427-432.
15. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367-2373.
16. Sung L, King SM, Carcao M, et al. Adverse outcomes in primary hemophagocytic lymphhistiocytosis. J Pediatr Hematol Oncol. 2002;24:550-554.
17. Beutel G, Wiesner O, Eder M, et al. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care. 2011;15:R80.
18. Karapinar B, Yilmaz D, Balkan C, et al. An unusual cause of multiple organ dysfunction syndrome in the pediatric intensive care unit hemophagocytic lymphohistiocytosis. Pediatr Crit Care. 2009;10:285-290.
19. Matsumoto Y, Naniwa D, Banno S, et al. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher. 1998;2: 300-304.
20. Satomi A, Nagai S, Nagai T, et al. Effect of plasma Exchange on refractory hemophagocytic syndrome complicated with myelodysplastic syndrome. Ther Apher. 1999;3: 317-319.